Her Small Biopsy Led to a $5,800 Denial. The Appeal Won.

The denial letter arrived 17 days after the blood draw. It was one page, and the number that mattered was easy to find: $5,800.

At 59, Maria, a composite subject, had spent more than three decades working as a self-employed hairdresser in South Jersey. She rented her station, bought her own health insurance and earned money only when someone sat in her chair. Cancer had already taken workdays for scans, appointments and a lung biopsy. Now the letter suggested she might owe nearly two months of her usual take-home income for a test her specialist said could help settle the treatment plan.

The insurer's explanation was harder to follow. It said the blood-based test did not meet its coverage criteria and pointed toward testing tumor tissue instead.

That sounded orderly. It was also the problem. The hospital had already tried to use the tissue.

The sample answered one question, then ran short

Maria's biopsy had provided enough material for the pathology team to identify non-small cell lung cancer, or NSCLC. It had not provided enough for all the broader biomarker testing her oncology team wanted before finalizing treatment.

Biomarker testing looks for features in cancer cells that may affect which treatments a specialist considers. A broad panel can examine many genetic changes at once. In Maria's case, the small biopsy sample had been divided among the work needed to establish what the tissue showed, and the remaining material was limited. The pathology report used restrained laboratory language.

Her specialist translated it: there was too little usable tumor left for the full set of tests.

A second tissue biopsy was discussed, but it was not treated as a minor repeat errand. It would mean another procedure, another interruption to work and another attempt to reach a lung lesion that had yielded only a small sample the first time.

The oncology team ordered a blood-based test, often called a liquid biopsy. It looks in blood for fragments of genetic material released by a tumor. The jargon makes the test sound like a replacement for tissue in every circumstance. It is not.

A blood test may find a relevant change, but an uninformative result may still leave questions because some tumors shed little detectable material into the bloodstream.

For Maria, the test had a narrower purpose: try to obtain broader information without immediately repeating the invasive biopsy. The insurer's denial flattened that clinical sequence into a rule about preferring tissue, even though the available tissue had already run out.

Maria read the letter twice at her kitchen table. Her daughter read it next and circled $5,800. Then she wrote four dates in the margin: the biopsy, the pathology result, the blood draw and the arrival of the denial.

That marked the beginning of the appeal.

The appeal had to connect the records

Maria first called the number on the back of her insurance card. The representative could see the denial but could not explain the pathology record behind it. Maria learned that an appeal could include supporting medical records and that her oncology office could request urgent review because treatment planning was still unsettled.

An appeal is a request for the insurer to reconsider a coverage decision. In plain English, it means showing why the facts of one case do not fit the assumption used to deny it. Here, the assumption was that adequate tumor tissue remained available for broader testing.

Her daughter kept the denial letter at the front of a folder. Behind it went the pathology report, the oncology visit summary and the insurer's coverage explanation. The folder was not impressive. Its value was that the papers told the story in the right order, while the denial had treated the blood test as though it had been ordered without any tissue work first.

The oncology office handled the clinical part. A staff member obtained the pathology documentation showing the limited sample, and her specialist submitted an appeal explaining that broader biomarker information could affect treatment selection, that the existing tissue was insufficient and that another procedure carried burdens the blood test might avoid. He filled out the insurer's paperwork and marked the request urgent.

Maria's job was smaller but exhausting. She authorized the office to send records, checked that the appeal had been received and wrote each update on the back of the denial letter. The insurer had the pathology report. The insurer had the specialist's explanation.

The review was pending.

Treatment planning did not stop, but it did not feel settled either. Her specialist discussed an initial option that could begin if the test produced no usable result, while also explaining that a detected biomarker might change the plan. Maria heard both parts. What stayed with her was that a coverage decision was now occupying days her medical team wanted to use for making a treatment decision.

She canceled clients when appointments required it and kept others because rent was still due. The $5,800 figure followed her to work. She did not tell every client why she had started leaving gaps in her schedule, and she did not know whether the testing company would eventually bill her for the denied amount. The lab placed the balance on hold during the appeal, which stopped collection activity but did not erase the denial.

What changed the insurer's decision

Nine days after the urgent appeal was submitted, the insurance portal showed the test as approved. A written notice followed.

The successful appeal did not depend on a moving personal statement or a perfect phone call. In Maria's case, it depended on one contradiction being made impossible to miss: the insurer had pointed to tissue testing, while the pathology record showed why sufficient tissue was no longer available.

The denial letter stayed in the folder. Maria's daughter crossed out $5,800 only after the updated insurance paperwork showed the charge had been processed under the plan, leaving Maria with a $95 laboratory cost share. Until then, neither of them trusted the portal status by itself.

The blood test later detected a biomarker that her specialist considered relevant. Her oncology team used that result with the rest of her medical record to finalize a plan involving an oral targeted treatment. That was one person's result, not a promise built into the testing process. The appeal had secured coverage for the test; it had not guaranteed what the blood would show.

Maria kept working through the review and the early treatment appointments, though with fewer clients each week. Her daughter continued bringing the folder because new insurance explanations kept appearing, some labeled as notices rather than bills and some displaying amounts that had already been adjusted. The original denial letter remained at the front, now carrying dates, brief notes and the crossed-out figure.

What worked for her was the oncology team's decision to appeal urgently and send the pathology evidence with its explanation, rather than arguing only that biomarker testing was generally useful. The records showed the missing fact. There was not enough tissue.

Questions people ask

Why would an insurer deny a blood-based biomarker test after a small biopsy?

In Maria's case, the insurer applied coverage language that favored tumor-tissue testing without accounting for the fact that her available sample had been used and was insufficient for broader testing. The appeal connected the pathology record to the reason the blood test had been ordered.

Is a liquid biopsy the same as testing tumor tissue?

No. A liquid biopsy looks in blood for genetic material released by a tumor, while tissue testing examines a sample taken from the tumor. Maria's specialist explained that the blood test might provide useful information, but an uninformative result would not necessarily answer every biomarker question.

What records mattered in her insurance appeal?

The decisive records were the pathology documentation showing limited tissue and the specialist's explanation of how broader biomarker information related to treatment planning. Her daughter also kept the denial and visit summary together, which made it easier to confirm that the insurer had received the same sequence of events.

Did approval mean she owed nothing?

No. Approval changed the test from a denied $5,800 charge to a covered service processed under her plan. Her final paperwork showed a $95 cost share, and her daughter crossed out the larger number on the denial letter only after that updated notice arrived.